Bloomage BioTechnology (688363) Q3 2026 earnings summary

Executive summary

• Q3 revenue was RMB 839.84m, down 6.96% YoY; attributable net income rose 5.62% to RMB 33.30m as operating efficiency improved.

• Strategy emphasized business-structure optimization, tighter cost control, AI deployment and synthetic biology to shift from scale expansion toward quality growth.

Financial highlights

• Q3 revenue was RMB 839.84m, down 6.96% YoY; total profit was RMB 37.46m, down 17.94% YoY.

• Q3 attributable net income was RMB 33.30m, up 5.62% YoY; adjusted for non-recurring items, net income was RMB 30.99m, up 165.00% YoY.

• 9M revenue was RMB 2.596bn, down 17.94% YoY; attributable net income was RMB 186.09m, down 26.27% YoY.

• 9M total profit was RMB 189.54m, down 34.98% YoY; basic EPS was RMB 0.39, down 25.00%.

Outlook and guidance

• Priorities include AI-enabled operations, synthetic biology, full-industry-chain collaboration and converting technology advantages into product competitiveness and customer value.

• The stated long-term aim is a life-health product and service system spanning multiple use cases and life stages, supporting high-quality and sustainable growth.